How will new and forthcoming clinical data change the management of essential thrombocythemia, polycythemia vera, and myelofibrosis? Here’s my take.
Read how I approach the most pressing clinical issues in diagnosis and management of polycythemia vera, essential thrombocythemia, and myelofibrosis.
In this commentary, I review key data from ASCO and EHA 2019 on investigational treatments for patients with myelofibrosis or polycythemia vera.
In this interactive, CME/CE/CPE-certified module, review practical guidance and the most recent data informing optimal treatment strategies for essential thrombocythemia, polycythemia vera, and myelofibrosis.
Download these slides to review current clinical data and best practices in managing patients with ET, PV, and MF, and then use the slides in your own presentations.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.